I'm expecting a bit more revenue, around $75 Million; this will give 6% revenue growth and 14% EBITDA growth and, at the same time, meet the lower end of the December Guidance.
I must admit that, given RXP's chronic underperformance in PE terms over the last 3 years and the (perversely) excellent operating performance it is not a tasty take-over morsel.